Allschwil, Switzerland, July 17, 2019
Polyphor today announced that it has decided to close the Phase III PRISM MDR and UDR studies of murapavadin intravenous (i.v.) for hospital-acquired and ventilator-associated bacte-rial pneumonia (HABP/VABP) which have been put on a voluntary temporary hold on May 9th, 2019.
Full PR available here